Home › NDC Lookup › RxCUI directory › RxCUI 2637875

Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel [Abreva Rapid Pain Rel... — RxCUI 2637875

Name: Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel [Abreva Rapid Pai… (RxCUI 2637875)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2637875 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2637875

Official nameGlycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel [Abreva Rapid Pain Relief]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asAbreva Rapid Pain Relief (glycerin 20 % / lidocaine hydrochloride 4 % ) Topical Gel; Abreva Rapid Pain Relief 20 % / 4 % Topical Gel

FDA products mapped1

Package NDCs mapped1

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lidocaine Transdermal Patch: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

This patch is used to treat post-herpetic neuralgia — that's the persistent burning or aching nerve pain that sometimes sticks around after a shingles outbreak, even after the rash...
What is this patch actually for — why did my doctor prescribe it?
You wear it for up to 12 hours, then take it off for the next 12 hours — think of it as '12 hours on, 12 hours off.' Your prescriber may allow up to 3 patches at a time, but never...
How long do I wear the patch, and can I wear more than one?

📖 Read our full Lidocaine Transdermal Patch guide →

🕸️ Concept Web — How Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.0... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel [Abreva Rapid Pain Relief] RxCUI 2637875 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Glycerin 4910 IN
- Lidocaine 6387 IN
- Glycerin / lidocaine 1602012 MIN
- Lidocaine hydrochloride 142440 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Abreva Rapid Pain Relief 2637871 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Glycerin / lidocaine Topical Gel 2637869 SCDF
- Glycerin / lidocaine hydrochloride Topical Gel 2647187 SCDFP
- Glycerin / lidocaine Topical Product 1602010 SCDG
- Glycerin / lidocaine hydrochloride Topical Product 2661003 SCDGP
- Glycerin / lidocaine Topical Gel [Abreva Rapid Pain Relief] 2637874 SBDF
- Glycerin / lidocaine hydrochloride Topical Gel [Abreva Rapid Pain Relief] 2655800 SBDFP
- Abreva Rapid Pain Relief Topical Product 2637873 SBDG
- Topical Gel 346286 DF
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel 2637870 SCD
- Glycerin 0.2 MG/MG 581681 SCDC
- Lidocaine hydrochloride 0.04 MG/MG 1010076 SCDC
- Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG [Abreva Rapid Pain Relief] 2637872 SBDC

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG Topical Gel SCD · 2637870
Glycerin 0.2 MG/MG SCDC · 581681
Lidocaine hydrochloride 0.04 MG/MG SCDC · 1010076
Glycerin / lidocaine Topical Gel SCDF · 2637869
Glycerin / lidocaine hydrochloride Topical Gel SCDFP · 2647187
Glycerin / lidocaine Topical Product SCDG · 1602010
Glycerin / lidocaine hydrochloride Topical Product SCDGP · 2661003

Brand-Name Concepts

Glycerin 0.2 MG/MG / lidocaine hydrochloride 0.04 MG/MG [Abreva Rapid Pain Relief] SBDC · 2637872
Glycerin / lidocaine Topical Gel [Abreva Rapid Pain Relief] SBDF · 2637874
Glycerin / lidocaine hydrochloride Topical Gel [Abreva Rapid Pain Relief] SBDFP · 2655800
Abreva Rapid Pain Relief Topical Product SBDG · 2637873
Abreva Rapid Pain Relief BN · 2637871

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 2637875 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00135-0400-01	1 TUBE in 1 PACKAGE (0135-0400-01) / 3 g in 1 TUBE	ABREVA Rapid Pain Relief	Haleon US Holdings LLC	2023-06-01

Observed labelers: Haleon US Holdings LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.